Loading...
Market
CagriSema weight loss percentage milestone in 2025
2
Resolution / Starting Odds
Less than 22.7% • 25%
22.7% to 24.9% • 25%
25% to 27% • 25%
More than 27% • 25%
Clinical trial results and official press releases
Story
Novo Nordisk Shares Drop 27% After CagriSema's 22.7% Weight Loss Misses Target
Dec 20, 2024, 11:46 AM
Novo Nordisk's shares plummeted by up to 27%, the most significant drop since April 2002, after the company's experimental obesity drug CagriSema failed to meet weight-loss expectations in a pivotal Phase 3 trial. The REDEFINE 1 trial demonstrated that patients receiving CagriSema achieved an average weight loss of 22.7% after 68 weeks, falling short of the anticipated 25% target. The company's market capitalization shrank by over 1,000 billion kroner. The disappointing results have raised concerns about Novo Nordisk's ability to compete in the rapidly growing weight-loss market, particularly against rivals like Eli Lilly and Viking Therapeutics. Eli Lilly's shares surged, while Viking Therapeutics' shares also rose on the news. Additionally, only 57% of patients in the trial reached the highest dose of CagriSema, prompting questions about the drug's tolerability. The Danish krone declined amid worries about the potential impact on Denmark's economy.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%
Achieve target weight loss in all regions • 25%
Achieve target weight loss in some regions • 25%
No region achieves target weight loss • 25%
Trials discontinued • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%